Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04489888
Title A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)
Recruitment Recruiting
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

head and neck squamous cell carcinoma

Therapies

Carboplatin + Paclitaxel + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.